Breaking News
Sort by:
Top Post
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Fluent BioSciences Launches Industry's Most Accessible, Cost-effective and Scalable Technology (PIPseq™) to Accelerate Adoption of Single-cell RNA Sequencing in Any Laboratory
Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every […]
Fluent BioSciences Launches Industry's Most Accessible, Cost-effective and Scalable Technology (PIPseqTM) to Accelerate Adoption of Single-cell RNA Sequencing in Any Laboratory
Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every […]
Fluent BioSciences and NanoCellect Announce Joint Collaboration to Improve Resolution of Single-cell RNA Sequencing Analysis of Rare Cell Populations
Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every […]
Fluent BioSciences Awarded $1.7 Million SBIR Grant to Commercialize PIPseq™, a Breakthrough Platform Technology Enabling Scalable, Sensitive Single-cell Analysis in Any Laboratory
Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more